Clinical trials: Spondylitis
Ankylosing Spondylitis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).
- Trial name
- BE MOBILE 2 (NCT03928743)
- Testing
- Bimekizumab
- Where
- 83 sites in United States, Belgium and 12 more
- Volunteers
- 332 people
- Sponsor
- UCB Biopharma SRL
Spondyloarthritis
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently.
- Trial name
- SELECT-AXIS 2 (NCT04169373)
- Testing
- Upadacitinib
- Where
- 212 sites in United States, Argentina and 23 more
- Volunteers
- 734 people
- Sponsor
- AbbVie
Ankylosing Spondylitis
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
The purpose of this study is to evaluate the efficacy of intravenously (administration of a fluid into the vein) administered golimumab 2 milligram per kilogram (mg/kg) in participants with active ankylosing spondylitis (chronic…
- Trial name
- NCT02186873
- Testing
- Golimumab
- Where
- 45 sites in United States, Australia and 7 more
- Volunteers
- 208 people
- Sponsor
- Janssen Research & Development, LLC
Axial Spondyloarthritis
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis
The purpose of this study is to assess the efficacy of ustekinumab, in adult anti-TNF(alpha) refractory participants with active radiographic axial spondyloarthritis (AxSpA), as measured by the reduction in signs and symptoms of…
- Trial name
- NCT02438787
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
- Where
- 148 sites in United States, Argentina and 17 more
- Volunteers
- 315 people
- Sponsor
- Janssen Research & Development, LLC
Spondylitis, Ankylosing, Arthritis, Psoriatic
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
The purpose of this study is to assess the safety of subcutaneous (SC) golimumab in participants with active Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) over 24 weeks.
- Trial name
- NCT03733925
- Testing
- Golimumab
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Johnson & Johnson Private Limited
Ankylosing Spondylitis
An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis
An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of RemsimaTM in Patients with Ankylosing Spondylitis
- Trial name
- NCT02557308
- Volunteers
- 329 people
- Sponsor
- Celltrion
Ankylosing Spondylitis
A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis
This is a study to assess the long term safety and tolerability of bimekizumab in subjects with ankylosing spondylitis
- Trial name
- BE AGILE 2 (NCT03355573)
- Testing
- Bimekizumab
- Where
- 50 sites in United States, Bulgaria and 8 more
- Volunteers
- 255 people
- Sponsor
- UCB Biopharma SRL
Ankylosing Spondylitis, Coxitis
Clinical and Radiological Manifestations of Coxitis in Patients With Ankylosing Spondylitis Treated With Golimumab
Rationale. Coxitis in AS is inflammation of hip(s) affecting significant number of patients. It is associated with worse function and more expressed axial disease requiring hip replacement at end-stage.
- Trial name
- GO-COX (NCT03557853)
- Testing
- Golimumab Injection
- Where
- 6 sites in Russia
- Volunteers
- 39 people
- Sponsor
- MSD Pharmaceuticals LLC
Spondylitis, Ankylosing
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
The purpose of the study is to evaluate the efficacy and tolerability of two doses of etoricoxib compared to naproxen in the treatment of ankylosing spondylitis (AS).
- Trial name
- NCT01208207
- Testing
- Part I - etoricoxib 60 mg, Part I - etoricoxib 90 mg, Part I- naproxen 1000 mg
- Volunteers
- 1,015 people
- Sponsor
- Organon and Co
Ankylosing Spondylitis
Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA
The purpose of this global study was to demonstrate the efficacy, safety, and tolerability of an intravenous (i.v.) regimen of secukinumab compared to placebo in participants with active ankylosing spondylitis (AS) or…
- Trial name
- NCT04156620
- Testing
- Secukinumab
- Where
- 102 sites in United States, Belgium and 16 more
- Volunteers
- 527 people
- Sponsor
- Novartis Pharmaceuticals
Spondylitis, Ankylosing
A Study of CC-99677 in Participants With Active Ankylosing Spondylitis
This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety…
- Trial name
- AS SpA axSpA (NCT04947579)
- Testing
- CC-99677
- Where
- 63 sites in United States, China and 6 more
- Volunteers
- 167 people
- Sponsor
- Celgene
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis
The primary objective of this study is to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographical Axial Spondyloarthritis
- Trial name
- MANTA-RAy (NCT03926195)
- Testing
- Filgotinib, Standard of Care
- Where
- 71 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 109 people
- Sponsor
- Lakefront Biotherapeutics NV
Ankylosing Spondylitis
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
The purpose of this study is to demonstrate the impact of secukinumab on the progression of structural damage in the spine, as measured by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) in patients with Ankylosing…
- Trial name
- SURPASS (NCT03259074)
- Testing
- GP2017 (adalimumab biosimilar), AIN457 150 mg
- Where
- 171 sites in United States, Argentina and 27 more
- Volunteers
- 859 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis
The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared to certolizumab pegol in the treatment of subjects with active ankylosing spondylitis (AS).
- Trial name
- NCT03215277
- Testing
- Bimekizumab, Certolizumab pegol
- Where
- 34 sites in United States, Czechia and 6 more
- Volunteers
- 76 people
- Sponsor
- UCB Biopharma SRL
Ankylosing Spondylitis
A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis
This is a study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis (AS).
- Trial name
- BE AGILE (NCT02963506)
- Testing
- Bimekizumab
- Where
- 74 sites in United States, Bulgaria and 8 more
- Volunteers
- 303 people
- Sponsor
- UCB Biopharma S.P.R.L.
Spondyloarthritis
A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in Chinese participants with radiographic axial spondyloarthritis (r-axSpA).
- Trial name
- NCT04285229
- Testing
- Ixekizumab
- Where
- 19 sites in China
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Ankylosing Spondylitis (AS)
A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis
The purpose of this study is to evaluate the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs…
- Trial name
- SELECT-AXIS 1 (NCT03178487)
- Testing
- Upadacitinib
- Where
- 101 sites in United States, Australia and 19 more
- Volunteers
- 187 people
- Sponsor
- AbbVie
Crohn Disease, Ulcerative Colitis
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
National, prospective, multicentre observational study designed for eligible patients treated with Inflectra. Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the…
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- ReFLECT (NCT02925338)
- Testing
- QOL questionaire
- Where
- 67 sites in France
- Volunteers
- 1,431 people
- Sponsor
- Pfizer
Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo.
- Conditions
- Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
- Trial name
- C-AXSPAND (NCT02552212)
- Testing
- Certolizumab Pegol
- Where
- 105 sites in United States, Australia and 7 more
- Volunteers
- 317 people
- Sponsor
- UCB BIOSCIENCES GmbH
Non-radiographic Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
The purpose of this study was to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and safety up to Week…
- Trial name
- PREVENT (NCT02696031)
- Testing
- Secukinumab
- Where
- 139 sites in United States, Australia and 22 more
- Volunteers
- 555 people
- Sponsor
- Novartis Pharmaceuticals